Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 th , 2021 at 8:35am ET. The session entitled “HAE There- Development Landscape in Hereditary Angioedema (HAE)” will include an overview of the HAE treatment landscape, information about Catabasis’s lead program QLS-215, and a Q&A session.
A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740 , and will also be available in the investors section of the Company’s website, www.catabasis.com , and will be archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005076/en/
Investor relations:
Andrea Matthews
investors@catabasis.com
Media:
Elizabeth Higgins
media@catabasis.com